New eczema ointment shows promise in Late-Stage trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adolescents aged ≥ 12 to 17 years, inclusive, and men and women aged ≥18 years. 2. Clinical diagnosis of mild to moderate atopic dermatitis (AD) for at least 1 year prior to Day 1. 3. Participants meet all the following atopic dermatitis criteria: VC period: IGA 2 to 3, affected BSA 3% to 20% (excluding scalp) at the baseline visit. LTS period: IGA 0 to 4, affected BSA 0% to 20% (excluding scalp) at Week 8. 4. Participants who agree to discontinue all agents used to treat AD from screening through the final follow-up visit. 5. Participants who have at least one AD lesion not located on the hands, feet, or genitalia. 6. Willingness to avoid pregnancy or fathering of children. - Exclusion Criteria: 1. Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline. 2. Concurrent conditions and history of other diseases: * Immunocompromised. * Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline. * Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline. * Any other concomitant skin disorder, pigmentation, or extensive scarring that, in the opinion of the investigator, may interfere with the evaluation of AD lesions or compromise participant safety. * Presence of AD lesions only on the hands or feet without prior history of involvement of other classical areas of involvement such as the face or the folds. * Other types of eczema. 3. Clinically significant cardiac disease; new cerebral infarction within 6 months from dosing; malignancies within 5 years from dosing; low hemoglobin; severe renal disease on dialysis; liver disease. 4. Systemic corticosteroids treated within 4 weeks before dosing; immunizations or sedating antihistamines treated within 4 weeks before dosing; other topical treatments for AD within 1 week before dosing. 5. Previously received Janus kinase (JAK) inhibitors, systemic or topical. 6. Ultraviolet light therapy or prolonged exposure to UV radiation within 2 weeks before dosing. 7. Liver function tests: AST or ALT ≥ 2 × ULN; alkaline phosphatase and/or bilirubin \> 1.5 × ULN. 8. Pregnant or lactating participants, or those considering pregnancy. 9. Alcohol or drug abuse. -